Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pimecrolimus

FDA-approved product (cream, topical), marketed as Elidel, Pimecrolimus.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Pimecrolimus
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atopic eczema
  • Eczematoid dermatitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Agents for dermatitis, excluding corticosteroids
FDA pharmacologic class
Calcineurin Inhibitor Immunosuppressant FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli51.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae48.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pimecrolimus in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pimecrolimus with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion

    NCT00925730 · start 2004-03

    Registered record
    Registry ID
    NCT00925730
    Conditions
    Atopic Dermatitis
    Interventions
    Pimecrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-03
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionPimecrolimus
    PhasePhase 4
    Registry statusCompleted

  • Cutaneous Lupus Erythematosus and Elidel

    NCT00222183 · start 2003-06

    Registered record
    Registry ID
    NCT00222183
    Conditions
    Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid
    Interventions
    Elidel (pimecrolimus)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2003-06
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid
    InterventionElidel (pimecrolimus)
    PhaseNot applicable
    Registry statusWithdrawn

  • Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis

    NCT00666159 · start 2002-12

    Registered record
    Registry ID
    NCT00666159
    Conditions
    Dermatitis, Atopic
    Interventions
    tacrolimus ointment; pimecrolimus cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-12
    Completion
    2003-05
    Enrolment
    226

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatitis, Atopic
    Interventiontacrolimus ointment; pimecrolimus cream
    PhasePhase 4
    Registry statusCompleted

  • Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis

    NCT00667160 · start 2002-12

    Registered record
    Registry ID
    NCT00667160
    Conditions
    Dermatitis, Atopic
    Interventions
    tacrolimus ointment; pimecrolimus cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-12
    Completion
    2003-11
    Enrolment
    426

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatitis, Atopic
    Interventiontacrolimus ointment; pimecrolimus cream
    PhasePhase 4
    Registry statusCompleted

  • Steroid-Sparing Effect With Pimecrolimus in Pediatric Patients With Atopic Dermatitis

    NCT00351052 · start 2001-12

    Registered record
    Registry ID
    NCT00351052
    Conditions
    Atopic Dermatitis
    Interventions
    Pimecrolimus; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-12
    Completion
    2004-09
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionPimecrolimus; Placebo
    PhasePhase 3
    Registry statusCompleted